Susquehanna Fundamental Investments LLC Acquires Shares of 347,271 Tango Therapeutics, Inc. (NASDAQ:TNGX)

Susquehanna Fundamental Investments LLC bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 347,271 shares of the company's stock, valued at approximately $1,073,000. Susquehanna Fundamental Investments LLC owned about 0.32% of Tango Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TNGX. Virtus ETF Advisers LLC lifted its holdings in shares of Tango Therapeutics by 127.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 24,945 shares of the company's stock worth $77,000 after acquiring an additional 13,961 shares during the last quarter. Nebula Research & Development LLC boosted its holdings in shares of Tango Therapeutics by 376.3% in the 4th quarter. Nebula Research & Development LLC now owns 51,924 shares of the company's stock worth $160,000 after purchasing an additional 41,023 shares in the last quarter. Blue Owl Capital Holdings LP purchased a new position in shares of Tango Therapeutics during the 4th quarter valued at about $5,352,000. Price T Rowe Associates Inc. MD grew its position in Tango Therapeutics by 29.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company's stock valued at $65,000 after acquiring an additional 4,813 shares during the last quarter. Finally, TRV GP VI LLC bought a new position in shares of Tango Therapeutics during the 4th quarter valued at $600,000. Hedge funds and other institutional investors own 78.99% of the company's stock.

Tango Therapeutics Stock Performance

Shares of NASDAQ TNGX traded down $0.06 during trading hours on Wednesday, hitting $1.21. The company's stock had a trading volume of 53,505 shares, compared to its average volume of 1,075,404. The business has a 50-day simple moving average of $1.56 and a 200-day simple moving average of $2.80. Tango Therapeutics, Inc. has a 12 month low of $1.11 and a 12 month high of $12.02. The stock has a market cap of $130.27 million, a price-to-earnings ratio of -1.02 and a beta of 1.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. On average, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of Tango Therapeutics in a report on Monday, April 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $12.33.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.